The second quarter results included a net gain of $5.7 billion from the sale of the company’s stake in GlaxoSmithKline’s consumer healthcare joint venture.
Core net income hit $3.01 billion in the second quarter of 2018, up from $2.87 billion from the same quarter a year prior.
Net sales for the quarter rose 7 percent to $13.16 billion, compared to 12.24 billion in the second quarter of 2017. The growth in sales was largely driven by oncology drugs, which grew 10 percent, as well as a 40 percent increase in sales for Cosentyx, a psoriasis drug, and 113 percent increase in sales of Entresto, a drug to treat heart failure.
“We made significant progress this quarter to transform Novartis into a focused medicines company, Novartis CEO Vas Narasimhan said. “Operationally, we delivered solid growth, with margins expanding and key growth drivers, including Cosentyx, delivering strong performance.”
More articles on pharmacy:
Packaging concerns force Novartis, Sandoz to recall 12 drugs
Pfizer stock value dips after Trump’s tweet
8 lesser-known facts about Pfizer
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
